# B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximab

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/b-cell-depletion-as-a-novel-treatment-for-systemic-lupus-erythematosus-a-phase-i/

## Facts

| Field | Value |
| --- | --- |
| Author Names | R. John Looney,Jennifer H. Anolik,Debbie Campbell,Raymond E. Felgar,Faith Young,Lois J. Arend,James A. Sloand,Joseph D. Rosenblatt,Iñaki Sanz |
| Citations | 779 |
| DOI | 10.1002/art.20430 |
| Fields | Immunology and Microbiology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2089016290 |
| PMID | 15334472 |
| Type | article |
| Year | 2004 |

## Paper authors

- [James A. Sloand](https://scholariq.org/researchers/james-a-sloand/)

## Paper primary topic

- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)

## Paper topics

- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [T-cell and B-cell Immunology](https://scholariq.org/topics/t-cell-and-b-cell-immunology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.